Precio por envase (10 viales). El descuento se aplica únicamente a este compuesto; no se admiten combinaciones.
| 10 mg | ||
|---|---|---|
| Cantidad | Precio por paquete | Ahorros |
| 1 paquete | 200 dólares por paquete | |
| 2 paquetes | 170 dólares por paquete | 15 % de descuento |
| 3 paquetes | 144 dólares por paquete | 28 % de descuento |
| 5 paquetes | 130 dólares por paquete | 35 % de descuento |
| 10 paquetes | 117 dólares por paquete | 42 % de descuento |
| 25 paquetes | 105 dólares por paquete | 48 % de descuento |
Melanotan 2 (MT-2) is a cyclic heptapeptide analogue of alpha-melanocyte stimulating hormone (α-MSH) developed alongside MT-1 at the University of Arizona during the 1980s by Mac Hadley, Victor Hruby, and colleagues. The cyclic structure — introduced via a lactam bridge between lysine and aspartate residues — confers metabolic stability and, critically, alters the receptor binding profile relative to the linear MT-1. MT-2 engages MC1R, MC3R, and MC4R, producing a broader range of downstream effects. This non-selectivity distinguishes MT-2 from MT-1 as a research tool and led to the derivation of bremelanotide (PT-141), a closely related compound that reached FDA approval for hypoactive sexual desire disorder in 2019.
MC4R expression is concentrated in the hypothalamus and limbic system, where it modulates sexual arousal, feeding behavior, and autonomic tone. MC3R is involved in energy homeostasis and feedback regulation of melanocortin signaling. MT-2’s concurrent engagement of all three receptors makes it a useful probe for mapping interactions between pigmentation, central arousal pathways, and metabolic signaling — effects that cannot be disentangled with MC1R-selective compounds like MT-1. Researchers studying cross-receptor melanocortin dynamics or comparing selective vs. non-selective agonist profiles use MT-2 as the broader-spectrum reference compound.
| Mecanismo | Efecto |
|---|---|
| MC1R agonism → MITF upregulation | Eumelanin synthesis; pigmentation observed in melanocyte studies |
| MC4R agonism in hypothalamus | Central arousal pathway activation; studied in sexual function models |
| MC3R agonism | Energy homeostasis signaling; autoreceptor feedback modulation |
| Dopaminergic pathway interaction (indirect, via MC4R) | Reward circuit modulation observed in rodent behavioral studies |
| Cyclic lactam structure → extended plasma half-life vs linear α-MSH | Sustained receptor occupancy; useful for longer-duration research protocols |
Melanotan 2 is used in studies examining:
| Formato | Polvo liofilizado |
| Pureza | ≥99% |
| Alias | MT-2, melanotan II, cyclo(Nle4-c[Asp5, D-Phe7, Lys10])-α-MSH(4–10) |
| Tallas disponibles | 10 mg |
| Almacenamiento | 2–8 °C sin abrir; estable durante más de 12 meses |
| Uso | Solo para fines de investigación — No apto para uso humano |
Melanotan 2 arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:
Total en mg ÷ Volumen añadido (mL) = Concentración (mg/mL)
Ejemplo: vial de 10 mg + 2 ml de agua destilada = solución de 5 mg/ml
El péptido reconstituido debe conservarse a una temperatura de entre 2 y 8 °C y utilizarse en un plazo de 28 a 30 días.
Published research provides a range of administered quantities for context. Early University of Arizona human studies used weight-based dosing in the 0.025–0.1mg/kg range. MT-2 served as the direct precursor to bremelanotide, which was refined for improved tolerability at lower doses.
Melanotan 2 is commonly paired in research settings with:
Cada lote tiene una pureza ≥99 %. Si sometes tu compuesto a un análisis independiente y los resultados no coinciden, envíanos el certificado de análisis (COA) y te concederemos un vale de compra sin hacerte preguntas.



